20.927 articles found

Metallic Nanocarriers for Therapeutic Peptides: Emerging Solutions Addressing the Delivery Challenges in Brain Ailments.

Rathnam SS, Deepak T, Sahoo BN, Meena T, Singh Y, Joshi A.

J Pharmacol Exp Ther · 2024-01-02

DOI: 10.1124/jpet.123.001689PMID: 37875308

Helicobacter pylori infection and Parkinson's Disease: etiology, pathogenesis and levodopa bioavailability.

Wei BR, Zhao YJ, Cheng YF, Huang C, Zhang F.

Immun Ageing · 2024-01-02

DOI: 10.1186/s12979-023-00404-1PMID: 38166953

Novel Pyrazolopyridine Inhibitors of Monoacylglycerol Lipase for the Treatment of Neurodegenerative Diseases and Neuroinflammation.

Rosse G.

ACS Med Chem Lett · 2024-01-02

DOI: 10.1021/acsmedchemlett.3c00548PMID: 38229740

Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis.

Hinojosa-Gonzalez DE, Zafar A, Saffati G, Kronstedt S, Zlatev DV, Khera M.

Prostate Cancer Prostatic Dis · 2024-01-02

DOI: 10.1038/s41391-023-00785-wPMID: 38167924

Chondroitin sulfate modulates oxidative stress and inflammation in the substantia nigra via gut microbiota regulation: Mechanistic insights into Parkinson's disease treatment

Gan L, Yu P, Wang K, Jiang W, Fu Y, Dong M.

Carbohydrate Polymers. · 2024-01-01

Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders.

Wiefels MD, Furar E, Eshraghi RS, Mittal J, Memis I, Moosa M, Mittal R, Eshraghi AA.

Curr Neuropharmacol · 2024-01-01

DOI: 10.2174/1570159x20666221003085508PMID: 36200211

Stem Cell Therapy for the Treatment of Parkinson's Disease: What Promise Does it Hold?

Nasrolahi A, Shabani Z, Sadigh-Eteghad S, Salehi-Pourmehr H, Mahmoudi J.

Curr Stem Cell Res Ther · 2024-01-01

DOI: 10.2174/1574888x18666230222144116PMID: 36815638

Neuroprotective Potential of Hesperidin as Therapeutic Agent in the Treatment of Brain Disorders: Preclinical Evidence-based Review.

Bansal K, Singh V, Singh S, Mishra S.

Curr Mol Med · 2024-01-01

DOI: 10.2174/1566524023666230320144722PMID: 36959141

Blood-brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches.

Khor SLQ, Ng KY, Koh RY, Chye SM.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/1871527322666230330093829PMID: 36999187

The Zebrafish Model as a New Discovery Path for Medicinal Plants in the Treatment of Parkinson's Disease.

Chahardehi AM, Hosseini Y, Mahdavi SM, Naseh I.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/1871527322666230330111712PMID: 36999188

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.

Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/1871527322666230331121028PMID: 36999711

Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.

Ciocca M, Pizzamiglio C.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/1871527322666230330122444PMID: 37005519